KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

A Phase 3 study to assess the safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in healthy infants in the USA and Puerto Rico.

James D Campbell, Sandeep Gupta, Mandeep Singh Dhingra, Betzana Zambrano, Lucia Gan, Siham B'Chir, Julie Chaix, Olga Syrkina, Julie Masson, Olga Liabis, Christine Rehm

Hum Vaccin Immunother 21(1) 2588874

PMID41337697
PMCIDPMC12688245
DOI10.1080/21645515.2025.2588874
发表日期2025-12-03
入排依据:未发现恶性肿瘤人群证据。
已检查 7 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;captionless-figure:AI 判定为 other;Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;另有 2 张未列出。
摘要

摘要

A quadrivalent meningococcal tetanus toxoid-conjugate vaccine, MenACYW-TT, has been developed to provide protection against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W. This Phase 3 study (NCT03537508; April 25, 2018, to September 22, 2023) evaluated the immunogenicity and safety of MenACYW-TT, compared with a licensed quadrivalent meningococcal oligosaccharide diphtheria CRM197-conjugate vaccine (MenACWY-CRM), in healthy infants ≥6 weeks of age when administered concomitantly with routine pediatric vaccines in a four-dose series (3 + 1 schedule). Functional antibodies against each meningococcal serogroup were measured by serum bactericidal antibody assay using human complement (hSBA). Non-inferiority was demonstrated for the first co-primary endpoint of seroresponse rates 30 days after the fourth dose at 12-15 months of age, with serogroup-specific seroresponse rates of 79.4%-97.6% and 77.6%-96.4% for MenACYW-TT and MenACWY-CRM, respectively. Non-inferiority was also demonstrated for the second co-primary endpoint based on proportions of participants with hSBA antibody titers ≥1:8 against each serogroup 30 days after the third dose at 6 months of age, with rates of 77.9-99.0% for MenACYW-TT and 67.7-92.9% for MenACWY-CRM. After four doses, hSBA geometric mean titers were comparable for serogroup A and higher for serogroups C, W, and Y with MenACYW-TT versus MenACWY-CRM. Immune responses to all routine pediatric vaccines administered concomitantly with MenACYW-TT were non-inferior to those following concomitant administration with MenACWY-CRM. MenACYW-TT and MenACWY-CRM were overall well tolerated, and the safety profiles of these vaccines were comparable. This study supports the use of MenACYW-TT in infants aged 6 weeks (42 days) or older.Study registration: ClinicalTrials.gov: NCT03537508.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
captionless-figureGraphical abstract
非 KM Figure
Figure 1Figure 1. Non-inferiority of the hSBA vaccine seroresponse rate 30 days after the fourth vaccination dose at 12 months of age in Group 1a versus Group 2a.
非 KM Figure
Figure 2Figure 2. Non-inferiority of the proportion of participants with hSBA antibody titers ≥1:8 at 30 days after the third dose in Group 1 versus Group 2.
非 KM Figure
Figure 3Figure 3. hSBA GMTs pre-dose four at 12 months of age and 30 days post-dose four in Group 1a versus Group 2a.
非 KM Figure
Figure 4Figure 4. Persistence of hSBA titers from 30 days after the third dose at 6 months of age through pre-dose four at 12 months of age in Group 1a versus Group 2a.
非 KM Figure
Figure 5Figure 5. Proportion of participants experiencing at least one (A) solicited injection site reaction after MenACYW-TT or MenACWY-CRM injection or (B) systemic reaction within 7 days after any vaccine dose, by maximum intensity.
非 KM Figure